目的探讨解郁汤联合电针百会、四神聪对脑梗死后抑郁焦虑患者的临床疗效及对神经功能的影响。方法将2016年4月—2018年3月医院收治的86例脑梗死后抑郁焦虑患者,随机分两组,为对照组和治疗组,各43例,对照组采用氟西汀胶囊(20 mg/次,1次/d...目的探讨解郁汤联合电针百会、四神聪对脑梗死后抑郁焦虑患者的临床疗效及对神经功能的影响。方法将2016年4月—2018年3月医院收治的86例脑梗死后抑郁焦虑患者,随机分两组,为对照组和治疗组,各43例,对照组采用氟西汀胶囊(20 mg/次,1次/d)治疗,观察组采用解郁汤联合电针百会、四神聪治疗,持续治疗8周。比较两组患者的临床疗效,治疗前、治疗4周、治疗8周时记录汉密尔顿焦虑量表(Hamilton Anxiety Scale,HAMA)、24项汉密尔顿抑郁量表(Hamilton Depression Scale,HAMD)、神经功能缺损程度(National Institute of Health stroke scale,NIHSS)评分和5-羟色胺(5-hydroxytryptamine,5-HT)、去甲肾上腺素(Norepinephrine,NE)。结果对照组有效率81.40%(35/43)低于观察组95.35%(41/43),差异具有统计学意义(P<0.05)。与治疗前比,两组患者治疗4周、治疗8周时HAMA评分、HAMD评分及NIHSS评分降低;与对照组比,观察组患者治疗4周、治疗8周时HAMA评分、HAMD评分及NIHSS评分较低,差异具有统计学意义(P<0.05)。与治疗前比,两组患者治疗4周、治疗8周时血清5-HT和NE含量升高;与对照组比,观察组患者治疗4周、治疗8周时血清5-HT和NE含量较高,差异具有统计学意义(P<0.05)。对照组不良率18.60%(8/43)与观察组20.93%(9/43)比较,差异无统计学意义(P>0.05)。结论解郁汤联合电针百会、四神聪对脑梗死后抑郁焦虑患者的临床疗效确切,可改善焦虑、抑郁及神经缺损表现,提高血5-HT和NE水平,安全性高,是一种安全有效的治疗方案。展开更多
Objective:To evaluate the efficacy and safety of Jianpi Jieyu Decoction(JJD)for treating patients with mild-to-moderate depression of Xin(Heart)-Pi(Spleen)deficiency(XPD)syndrome.Methods:In this multi-center,randomize...Objective:To evaluate the efficacy and safety of Jianpi Jieyu Decoction(JJD)for treating patients with mild-to-moderate depression of Xin(Heart)-Pi(Spleen)deficiency(XPD)syndrome.Methods:In this multi-center,randomized,controlled study,140 patients with mild-to-moderate depression of XPD syndrome were included from Xiyuan Hospital of China Academy of Chinese Medical Sciences and Botou Hospital of Traditional Chinese Medicine from December 2017 to December 2019.They were randomly divided into JJD group and paroxetine group by using a random number table,with 70 cases in each group.The patients in the JJD group were given JJD one dose per day(twice daily at morning and evening,100 m L each time),and the patients in the paroxetine group were given paroxetine(10 mg/d in week 1;20 mg/d in weeks 2-6),both orally administration for a total of 6 weeks.The primary outcome was the change of 17-item Hamilton Depression Rating Scale(HAMD-17)score at week 6 from baseline.The secondary outcomes included the Hamilton Anxiety Scale(HAMA)score,Traditional Chinese Medicine Symptom Scale(TCMSS),and Clinlcal Global Impression(CGI)scores at the 2nd,4th,and 6th weekends of treatment,HAMD-17 response(defined as a reduction in score of>50%)and HAMD-17 remission(defined as a score of 7)at the end of the 6th week of treatment.Adverse events(AEs)were also recorded.Results:From baseline to week 6,the HAMD-17 scores decreased 10.2±4.0 and 9.1±4.9 points in the JJD and paroxetine groups,respectively(P=0.689).The HAMD-17 response occurred in 60%of patients in the JJD group and in 50%of those in the paroxetine group(P=0.292);HAMD-17 remission occurred in 45.7%and 30%of patients,respectively(P=0.128).The differences of CGI scores at the 6th week were not statistically significant(P>0.05).There were significant differences in HAMD-17 scores between the two groups at 2nd and 4th week(P=0.001 and P=0.014).The HAMA scores declined 8.1±3.0 and 6.9±4.3 points from baseline to week 6 in the JJD and paroxetine groups,respectively(P=0.905 between gro展开更多
文摘目的探讨解郁汤联合电针百会、四神聪对脑梗死后抑郁焦虑患者的临床疗效及对神经功能的影响。方法将2016年4月—2018年3月医院收治的86例脑梗死后抑郁焦虑患者,随机分两组,为对照组和治疗组,各43例,对照组采用氟西汀胶囊(20 mg/次,1次/d)治疗,观察组采用解郁汤联合电针百会、四神聪治疗,持续治疗8周。比较两组患者的临床疗效,治疗前、治疗4周、治疗8周时记录汉密尔顿焦虑量表(Hamilton Anxiety Scale,HAMA)、24项汉密尔顿抑郁量表(Hamilton Depression Scale,HAMD)、神经功能缺损程度(National Institute of Health stroke scale,NIHSS)评分和5-羟色胺(5-hydroxytryptamine,5-HT)、去甲肾上腺素(Norepinephrine,NE)。结果对照组有效率81.40%(35/43)低于观察组95.35%(41/43),差异具有统计学意义(P<0.05)。与治疗前比,两组患者治疗4周、治疗8周时HAMA评分、HAMD评分及NIHSS评分降低;与对照组比,观察组患者治疗4周、治疗8周时HAMA评分、HAMD评分及NIHSS评分较低,差异具有统计学意义(P<0.05)。与治疗前比,两组患者治疗4周、治疗8周时血清5-HT和NE含量升高;与对照组比,观察组患者治疗4周、治疗8周时血清5-HT和NE含量较高,差异具有统计学意义(P<0.05)。对照组不良率18.60%(8/43)与观察组20.93%(9/43)比较,差异无统计学意义(P>0.05)。结论解郁汤联合电针百会、四神聪对脑梗死后抑郁焦虑患者的临床疗效确切,可改善焦虑、抑郁及神经缺损表现,提高血5-HT和NE水平,安全性高,是一种安全有效的治疗方案。
基金Supported by Special Funds for Fundamental Research Funds of Central-Level Public Welfare Research Institutes(No.ZZ0908001)Science and Technology Innovation Project(Major Research Project,No.CI2021A01312)Traditional Chinese Medicine Prevention and Treatment of Encephalopathy Inheritance and Innovation Team(No.CI2021B006)of China Academy of Chinese Medical Sciences。
文摘Objective:To evaluate the efficacy and safety of Jianpi Jieyu Decoction(JJD)for treating patients with mild-to-moderate depression of Xin(Heart)-Pi(Spleen)deficiency(XPD)syndrome.Methods:In this multi-center,randomized,controlled study,140 patients with mild-to-moderate depression of XPD syndrome were included from Xiyuan Hospital of China Academy of Chinese Medical Sciences and Botou Hospital of Traditional Chinese Medicine from December 2017 to December 2019.They were randomly divided into JJD group and paroxetine group by using a random number table,with 70 cases in each group.The patients in the JJD group were given JJD one dose per day(twice daily at morning and evening,100 m L each time),and the patients in the paroxetine group were given paroxetine(10 mg/d in week 1;20 mg/d in weeks 2-6),both orally administration for a total of 6 weeks.The primary outcome was the change of 17-item Hamilton Depression Rating Scale(HAMD-17)score at week 6 from baseline.The secondary outcomes included the Hamilton Anxiety Scale(HAMA)score,Traditional Chinese Medicine Symptom Scale(TCMSS),and Clinlcal Global Impression(CGI)scores at the 2nd,4th,and 6th weekends of treatment,HAMD-17 response(defined as a reduction in score of>50%)and HAMD-17 remission(defined as a score of 7)at the end of the 6th week of treatment.Adverse events(AEs)were also recorded.Results:From baseline to week 6,the HAMD-17 scores decreased 10.2±4.0 and 9.1±4.9 points in the JJD and paroxetine groups,respectively(P=0.689).The HAMD-17 response occurred in 60%of patients in the JJD group and in 50%of those in the paroxetine group(P=0.292);HAMD-17 remission occurred in 45.7%and 30%of patients,respectively(P=0.128).The differences of CGI scores at the 6th week were not statistically significant(P>0.05).There were significant differences in HAMD-17 scores between the two groups at 2nd and 4th week(P=0.001 and P=0.014).The HAMA scores declined 8.1±3.0 and 6.9±4.3 points from baseline to week 6 in the JJD and paroxetine groups,respectively(P=0.905 between gro
